SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRTX, HES, SIX, MIRO
Mirati Therapeutics Inc MRTX
News
-
Moore Kuehn Encourages PCTI, MRTX, CSTR, and BBAI Investors to Contact Law Firm
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRTX, GAN
MIRATI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SLGC, SP, MRTX
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – SIX, MRTX, FAZE, TGH
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SP, PCTI, MRTX
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – MRTX, FAZE, HES, TGH
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PNT, MRTX, ORTX
Moore Kuehn Encourages PNT, VERY, MRTX, and ORTX Investors to Contact Law Firm
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SP, MRTX, ICPT
MRTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Mirati Therapeutics, Inc. to Bristol Myers Squibb
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SP, OLK, ORTX, MRTX
Moore Kuehn Encourages SP, ORTX, MRTX, and SRT Investors to Contact Law Firm
Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CNSL, PCTI, SP, MRTX